Skip to main content
Premium Trial:

Request an Annual Quote

Anthony Pawson, Mark Smedley, Patrice Hugo, Tim Harkness, Richard Lussier, Walter Ausserer, Denis Dalton

The Inamori Foundation has named Anthony Pawson, a molecular biologist affiliated with the Samuel Lunenfeld Research Institute at Toronto’s Mount Sinai Hospital and the University of Toronto, as the recipient of this year’s Kyoto Prize in Basic Sciences.
The Kyoto Award is an international award that recognizes individuals for scientific, cultural, and spiritual achievements.
This year, the Basic Sciences prize was targeted at researchers specializing in molecular biology, cell biology, and neurobiology. The award is being given to Pawson in recognition of his contribution to the field of intracellular signal transduction, the foundation said.
Pawson demonstrated the presence and importance of a protein domain called the Src homology 2, or SH2, domain, which influences signal transduction related to cell division and metabolism and has a role in some cancer-like cellular processes.
Pawson received his PhD from the Imperial Cancer Research Fund in London and went on to post-doctoral studies at the University of California at Berkeley. He became an assistant professor at the University of British Columbia in Vancouver in 1981 and moved to the University of Toronto in 1985.
He also was a co-founder of MDS Proteomics, which later became Protana.

Invitrogen last week said Mark Smedley will be overseeing the integration of the company with Applied Biosystems.
Smedley has assembled a team of more than 30 “change agents” from both companies “who will take the best parts of their own organizations to plan for a stronger, better combination,” Greg Lucier, chairman and CEO of Invitrogen said in a statement.
Smedley is global head of operations at Invitrogen. Prior to joining the company, he was at Novartis. He has more than 20 years experience in the life sciences and pharmaceutical industry with positions in operations, R&D, sales, marketing, program management, and other posts.
Invitrogen announced earlier this month that it plans to acquire ABI for $6.7 billion. The new company, to be based in Carlsbad, Calif., will adopt the ABI name.

MDS Pharma Services has named Patrice Hugo as vice president of scientific affairs for its global central lab network, where he will lead the firm’s biomarker development activities.
Hugo joins MDS Pharma Services from Caprion Proteomics, where he was executive vice president of research and development. Prior to that, he was with Procrea BioSciences, first as vice president of scientific research and then as chief scientific officer. Before that, he worked for the Montreal Institute of Clinical Research.

Cell Biosciences, a startup developing nanofluidic systems for proteomic applications, has hired three managers. The company named Tim Harkness, formerly chief financial officer for Molecular Devices, as president and chief executive officer.
In addition, Richard Lussier was named vice president of sales and international operations. Lussier served in various sales and operations in the Applera businesses Applied Biosystems and Celera Genomics, including a stint as president and general manager of Applera’s Japanese subsidiary for five years. More recently, Lussier established the worldwide sales, service, and support organization for Solexa, now part of Illumina.
Cell Biosciences also hired Walter Ausserer as vice president of marketing. Ausserer most recently directed product development at Axela Biosensors. He previously held senior product development and marketing positions at Caliper Life Sciences and Dionex.

New England Peptide has hired Denis Dalton as a business development manager.
Dalton most recently served as business development manager for Debro Chemicals & Pharmaceuticals. Previously, he was territory manager for Dalton Chemical Laboratories and a sales representative for Anachemia Science.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.